This Groundbreaking Device Just Keeps Winning for Abbott Labs
In late September, Abbott Laboratories (NYSE: ABT) shared encouraging results from a study that tracked the efficacy of its FreeStyle Libre continuous glucose monitor (CGM) device for type 2 diabetes.
What were the results from the study that amounted to such great news for Abbott and type 2 diabetes patients? What impact could this have on the future sales of the franchise? Let's dig into the study's findings and the CGM market to answer these questions.
Abbott retrospectively observed 5,933 patients diagnosed with type 2 diabetes via the French national health claims database between Aug. 1, 2017, and Dec. 31, 2018. These patients followed a once-daily basal-only insulin treatment plan and used the FreeStyle Libre system to monitor their blood sugar (glucose) levels.
Source Fool.com
